Full recovery of excess fat buildup around lower spine using GLP-1 drug

Lumbar spinal epidural lipomatosis (SEL) is an uncommon cause of lumbar spinal canal stenosis, characterized by pathological overgrowth of unencapsulated epidural fat. SEL is most frequently associated with chronic corticosteroid exposure or morbid obesity, though idiopathic cases occur [1, 2]. Patients typically present with low back pain, neurogenic claudication, or radiculopathy; in advanced cases, cauda equina syndrome may develop. Management ranges from weight reduction and steroid withdrawal to surgical decompression. In practice, many patients ultimately undergo laminectomy or epidural fat debulking, but perioperative risks are considerable [3, 4].

Weight loss is the cornerstone of conservative therapy in obesity-related SEL. Case reports suggest that both bariatric surgery and nonsurgical weight loss can lead to radiographic and clinical improvement, indicating that epidural fat is metabolically responsive and that reducing systemic adiposity can decompress the spinal canal [5].

Glucagon-like peptide-1 (GLP-1) receptor agonists have recently emerged as effective pharmacologic therapy for obesity, inducing relevant weight loss with mainly transient gastrointestinal side effects. This makes GLP-1 agonists attractive for high-risk obese patients in whom surgery carries substantial risk [6]. These agents mimic the endogenous incretin hormone GLP-1, promoting glucose-dependent insulin secretion and suppressing glucagon. Crucially for weight loss, they delay gastric emptying and act on hypothalamic receptors to increase satiety and reduce appetite, leading to reduced caloric intake [7, 8].

Chronic low back pain in SEL poses an additional challenge. Opioids are often undesirable in obese patients because of side effects and dependency risk. Medical cannabis has gained attention as an adjunctive analgesic, providing modest pain relief and facilitating opioid sparing and improved function [9].

Here, we describe a case of severe lumbar SEL in a morbidly obese patient successfully managed without surgery. Combined GLP-1 agonist-induced weight loss and medical cannabis-assisted analgesia led to complete clinical and radiological resolution of SEL and obviated the need for decompressive surgery (Fig. 1).

A 48-year-old man presented with chronic low back pain that had progressively worsened over several years. His history was notable for morbid obesity (153 kg, body mass index ~46 kg/m2) without chronic steroid use, endocrinopathy or prior spine trauma. He reported exercise intolerance due to back and leg pain, but neurological examination showed full strength, intact sensation, normal reflexes and no bladder or bowel dysfunction.

Lumbar magnetic resonance imaging (MRI) demonstrated diffuse epidural fat from L3 to S1 consistent with SEL, with severe thecal sac compression and maximal canal narrowing at L5–S1 as seen in Fig. 1. Initial conservative management with physiotherapy, lifestyle-based weight loss advice, and non-opioid analgesics produced little benefit. Baseline pain was rated 8/10, and he could ambulate less than 500 m before stopping because of neurogenic claudication.

Given refractory symptoms and marked obesity, aggressive medical weight loss was initiated. The patient started subcutaneous semaglutide, titrated to 2.4 mg once weekly. In parallel, medical cannabis oil was introduced in low doses and titrated as an adjunct for pain control and to avoid opioids with the goal of improving tolerance for physical activity and physiotherapy.

The response was striking. Over seven months, the patient lost approximately 59 kg, reaching 93.8 kg, corresponding to nearly 39% total body-weight reduction (Fig. 3). Semaglutide was well tolerated apart from transient, mild nausea during dose escalation. Cannabis therapy provided satisfactory analgesia without sedation or cognitive blunting, enabling more intensive participation in exercise and rehabilitation. His back pain decreased to around 3/10, and his functional capacity improved from sedentary to walking up to ~24 000 steps per day.

At eleven months, repeat lumbar MRI showed marked regression of epidural lipomatosis (Fig. 2). Epidural fat volume at L3–S1 had decreased substantially, and the previously severe central canal stenosis had resolved, with normalization of thecal sac contour and canal dimensions. No new degenerative changes were detected. Clinically, the patient reported complete resolution of neurogenic claudication and only mild intermittent low back discomfort. In view of the radiologic and clinical improvement, decompressive surgery was deemed unnecessary.

This case illustrates successful non-surgical management of severe lumbar SEL through pharmacologically assisted weight loss combined with adjunctive cannabis-based analgesia. Although SEL is often regarded as an indication for decompressive surgery once significant stenosis is present, our patient’s course shows that, in the absence of acute neurological deficits, intensive conservative therapy targeting the underlying obesity can lead to both symptomatic and radiologic resolution.

Obesity was the most plausible driver of SEL in this patient. Previous reports have documented reversal of SEL with nonsurgical weight reduction and after bariatric surgery, suggesting that epidural fat is dynamic and responsive to negative energy balance [5, 10–13]. This case extends those observations by demonstrating near-complete reversal of SEL after extreme weight loss achieved with a GLP-1 receptor agonist rather than surgery.

Semaglutide and other GLP-1 agonists are appealing for high-risk spine patients with morbid obesity. They offer a non-invasive means to reduce surgical risk preoperatively and, as shown here, may in some cases eliminate the indication for surgery by treating the causative adiposity. The favorable safety profile observed in large obesity trials aligns with our patients experience [14, 15].

Effective pain management was equally important to break the cycle of inactivity and weight gain. Medical cannabis, introduced as an opioid-sparing strategy, allowed adequate pain control without opioids and facilitated a marked increase in physical activity. While evidence for cannabis in chronic low back pain is still evolving and benefits are generally modest, it can be a useful adjunct within multimodal pain management when conventional analgesics are ineffective or poorly tolerated [16, 17].

Avoiding surgery was advantageous. Morbidly obese patients undergoing lumbar decompression face elevated perioperative risks. Our patient was spared these risks and the recovery period associated with laminectomy. Nonetheless, conservative management of SEL is appropriate only when patients are neurologically intact. Acute cauda equina syndrome, progressive weakness, or intractable pain despite maximal conservative measures still mandate timely surgical decompression [18–20].

In this case of severe lumbar SEL associated with morbid obesity, combined GLP-1 receptor agonist therapy and medically supervised cannabis use led to major weight loss, complete radiologic regression of epidural lipomatosis, and full resolution of spinal canal stenosis without surgery. This experience supports an intensified, multidisciplinary conservative strategy in neurologically intact obese SEL patients, leveraging modern anti-obesity pharmacotherapy and individualized pain management before resorting to operative intervention.